Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”), the leading developer of spider silk based fibers, announces the rescheduling of the upcoming press conference. The Company’s operations have not been directly affected by COVID-19. To ensure continued safe operations for our staff and facility, the Kraig Labs research center will not be hosting any outside visitors for the next 30 days.

The Company will be introducing a game changing Spider Silk technological breakthrough during the upcoming online press conference. This conference will open to all press, stakeholders and interested parties via streaming on the Company’s website. The live webcast is now scheduled to take place on April 16 at 4:30 p.m. Eastern Time and will be broadcast on the Company website at www.kblbinvestors.com by navigating to “Webcasts”.

“While we’re eager to share this exciting scientific breakthrough, we decided, in light of the current COVID-19 situation, to reschedule the press conference. We are taking this obvious step in consideration of the continued good health of our staff and our Nation’s focus on aggressively addressing efforts to combat COVID-19. We are continuing to advance the business model and look forward to providing future updates on that progress,” said CEO and Founder Kim Thompson. “We are excited to unveil our latest breakthrough at the upcoming press conference on April 16^th.”

The webcast will be accessible on most operating systems and browsers. A webcast replay will be available, following the event, within the Investor Relations section of the Company’s web site.

The Company will publish a follow up release, just prior to the webcast, that will contain viewing details and interested parties are invited to sign up at www.kblbinvestors.com to receive an event reminder with viewing instructions.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”), the leading developer of spider silk based fibers, announces that management will host an online presentation to introduce a game changing Spider Silk technological breakthrough.

The online press conference is open to all press, stakeholders and interested parties. The live webcast will take place on March 19 at 4:30 p.m. Eastern Time and will be broadcast on the Company website at www.kblbinvestors.com by navigating to “Webcasts.”

The webcast will be accessible on most operating systems and browsers. A webcast replay will be available, following the event, within the Investor Relations section of the Company’s web site.

The Company will publish a follow up release, just prior to the webcast, that will contain viewing details and interested parties are invited to sign up at www.kblbinvestors.com to receive an event reminder with viewing instructions.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced that it has implemented new quality assurance management and production procedures at Prodigy Textiles, the Company’s Vietnamese subsidiary, based on lessons learned from its production rollout.

The Company embarked on an aggressive winter production rollout to accommodate urgent requests for materials from specific collaboration partners and potential customers. The result was a launch during what is normally the Vietnamese silk offseason. In this process we discovered and addressed two challenges, obtaining quality mulberry for feedstock and climate controls in the new facility during the offseason. The Company has addressed these issues as described below.

The production hiccup caused by the winter launch is not expected to impact the Company’s business plan or prospects. Kraig Labs intends to be first to market and is keeping the momentum going by continuing its breeding programs, as the Company’s plans to produce its first commercial batch of Dragon Silk are still in progress.

For the immediate production run, the winter temperature has resolved itself, as we enter February, which is generally considered a better month for rearing silk worms. Whereas, for the following winters, the Company will enhance its climate control protocols, to ensure uniform and consistent year round production.

Kraig labs has also taken steps to ensure that feedstock will not disrupt its future winter production cycle, by utilizing land set aside from the government to immediately plant an additional 40 acres of mulberry trees. This increased capacity and continuous supply of high quality mulberry is an important component of the Company’s production operations. This expansion of lands available to the Company and its work with the local farming cooperatives will allow for tighter control and ensure that this key input is readily available and of the highest quality.

Additionally, the Company installed and began utilizing specialized fiber testing equipment, which mirrors that of its research headquarter, in the United States, to monitor fiber performance, including tensile strength and elasticity. This equipment allows for the identification and selective mating of the best performing silkworms.

The Company has remained in communication with its collaboration partners, informing them of this temporary delay in shipping, who have been supportive of these production actions and look forward to receiving the highest quality fibers.

The Company’s technology is sound, as the tests of the Prodigy Textile production facility fibers mirror the results from its US laboratory. Kraig Labs will continue to monitor and implement procedures to ensure its product meets its high standards and its potential commercialization partners’ expectations.

“Kraig Labs is laser focused on the commercialization of our exceptional materials. Recognizing challenges to that vision and quickly adapting to overcome those obstacles is a core piece of our corporate DNA,” said COO Jon Rice. “By implementing the new processes, Kraig Labs continues to show its commitment to upholding sustainable fiber production and goals, as well as our commitment to our valued business partners. Despite our winter launch hiccup, we remain on track to meet our goal of delivering superior fibers to our clients.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”), the leading developer of spider silk based fibers, announced that it is providing an update on Prodigy Textiles’, the Company’s Vietnamese subsidiary, production operations.

The Company began production operations, at its Vietnamese subsidiary, in October of 2019. Due to climate conditions and farming cycles, silk is traditionally not produced during the winter in Vietnam. In its efforts to bring its revolutionary silk materials to market, as soon as possible, the Company pushed ahead, rearing its silkworms through the winter months.

The Company hoped to overcome the production challenges of operating in the off season by utilizing its temperature controlled laboratories. While initially highly successful, the Company began to face setbacks in sustaining production during this traditional off season. Fluctuating temperatures, and difficulties in sourcing high quality mulberry, led to production challenges. The Company has accelerated the planting of additional mulberry under contract and control to eliminate these issues for future production cycles.

The Company expects to re-ignite its production expansion over the next 30-45 days, as spring temperatures realign with production requirements. The Company will also use this growing season as an opportunity to improve its internal factory environmental control protocols. When all controls are in place, the Company believes that it can successfully reach year-round production.

“As with any company’s first large scale production run, we expected some delays and challenges. These small hurdles will cause a short delay, but we do not anticipate any negative impact to our long term plans, quality, or capacity,” said Jon Rice, COO. “We assembled an excellent team in Vietnam; they are tirelessly working to bring this vision of large scale spider silk production, from silkworms, to life. I am excited about the opportunities ahead for Kraig Labs and our eco-friendly spider silk materials.”

The outbreak of Coronavirus in China is not presently expected to have any significant impact on the Company or its operations. The Company does not source any materials or import from China, nor is China a major target market for the Company’s products.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., – Nov 26, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”) (“Kraig Labs”), the leading developer of spider silk based fibers, announced today the following letter to our shareholders from Kim Thompson, the Company’s Chairman, CEO, and founder.

Dear Kraig Biocraft Laboratories shareholders,

Our goal has always been to develop and produce the best spider silk based fibers.  Our suite of technological innovations has positioned Kraig Biocraft Laboratories to remain firmly in the leadership role. 2019 brought us the beginning of production operations, perhaps the most significant milestone in the Company’s work to commercialize spider silk since the creation of the first transgenics.

This year, Kraig Biocraft Laboratories officially transitioned into the increased production and scalability phase of our operations.  This operational focus will serve as the foundation in creating and maintaining long-term shareholder value. We are preparing to expand our footprint and deliver our largest ever commercial production of spider silk. 

In the coming months the Company will be delivering the first shipment of finished silk from the factory in Vietnam.  Simultaneously we are continuing to expand our production capacity.  With these developments, we are now preparing to fulfill material deliveries to numerous end markets that we are targeting for growth in 2020.

With our focus on the advancement of commercialization activities, we have determined that this is the time to elevate the Company from the OTC Markets Venture Exchange to a national exchange.  Our efforts to uplist to a national exchange are well underway, with several key pieces of this process complete.  We have elected four new board members, who stand ready to take their positions to fulfill governance requirements of the national exchanges.  We held our annual shareholder meeting and gained shareholder approval for our move to uplist. 

Securing expansion capital and listing on a national exchange will immediately impact the Company. This capital will address national exchange listing requirements and serve to underpin the Company’s work to rapidly expand capacity, build the inventory to grow our business, bring new products to market, and establish sales channel partnerships. This growth will benefit all of our shareholders.    

During the past 12 months our research team has been working quietly to deliver breakthroughs in technologies and new products in the lab.  Accelerating our development time cycle with the addition of new personnel and processes has delivered technologies and transgenics which I believe will take us far beyond Dragon Silk.  This year the Company continued to expand its intellectual property portfolio by filing the first five of many expected provisional patent applications.  We are also vigorously prosecuting the patent applications previously filed in conjunction with the University of Notre Dame.

We have shown tremendous growth in 2019 by hitting nearly every mark in our business plan.  That growth includes; obtaining approvals to commence rearing operations in Vietnam, completing the buildout of our factory in Vietnam, the initial scale up of our overseas production operations, advancements in our R&D and IP portfolio, strengthening our corporate governance in preparations for bigger things, and growth of our market cap by more than 285%. 

Our corporate developments over the last year have given us lots of reasons to be thankful.

Kraig Labs is now preparing to take a giant leap that will enhance our global presence.  Our management has been working hard over the last quarter to prepare for that leap and we believe those efforts will lead to even greater successes in 2020.  We intend to use our new position as a launching pad.

While I am thrilled over our progress and growth in 2019, this is only the foundation upon which we intend to build.  Our new assignment is to deliver spider silk to end customers and bring everything to fruition in 2020.

As we enter the holiday season I would like to express my personal appreciation to our shareholders.  We are thinking of their long term interests with every corporate decision we make.  I would also like to thank our exceptional teams at Kraig Labs and Prodigy Textiles.  I have great appreciation for the Kraig Labs family, including our outside contractors.

Thank you all for your support, and I wish you and your loved ones a Happy Thanksgiving and a blessed holiday.

Sincerely,

Kim Thompson

CEO, Chairman, and founder of Kraig Biocraft Laboratories, Inc.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – October 23, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has selected Jon Rice, the Company’s COO, to join its Board of Directors, as the Company advances and strengthens its corporate governance.

Rice has served as the COO of Kraig Biocraft Laboratories since 2015.  In this role, Rice has overseen and led operations at the Company’s domestic research and development headquarters as well as the recent breakthroughs in the scale-up of its international production operations, through its subsidiary, Prodigy Textiles Co., Ltd.  Prior to joining Kraig Labs, Rice served in a series of leadership roles developing and marketing advanced power systems, developed under contract with the US Department of Defense, which were successfully leveraged into commercial spinoff products.  Rice blends technical and business operations expertise, holding a degree in both engineering and a master’s in business administration.

“We are pleased to welcome Jon, with his first hand working knowledge and experience of implementing our operations, to the Kraig Labs board,” said chairman and CEO, Kim Thompson.  “Jon’s role and understanding of our Company, from the inside, will serve as a crucial bridge between day to day operational management and board governance.

The addition of Rice to the board will strengthen the overall skill set, perspective, and experience necessary to support and drive growth for all of the Company’s stakeholders.  Rice’s understanding of Kraig’s operations will provide a strong link to the board’s fiduciary oversight responsibilities.

Rice’s term is expected to begin this quarter.

Once formally seated, Rice, and the three recently announced new independent directors, will join Thompson to form the majority independent controlled board, which is intended to satisfy the uplisting requirement of a national exchange.

“I am excited for the opportunity to expand my service to Kraig Labs and our Shareholders in this new role, said Rice.  “The advancement we are making in all aspects of our business model, from research to governance and commercialization, make this a fantastic time to be part of Kraig Labs and our exciting growth.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – Sept 18, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has selected Mr. Anurag Gupta for its expanded Board of Directors.  Among the many significant accomplishments during his career, Mr. Gupta has served as: the CEO of Global Data Services for TBG, the President for Europe, Middle East, and Africa region for BrightPoint, Inc, and the Executive Vice President of the CMS Division at IHS Markit.  Mr. Gupta currently serves as an Independent Director on the boards of Roseburg Forest Products Co. and Drive My Way, Inc.

“We are pleased to welcome Anurag as the first, of several, new independent directors to be joining the Kraig Lab’s board,” said chairman and CEO, Kim Thompson.  “Anurag’s background and experience in corporate management, technology development, international operations, and investor relations will be an asset to the Company as we continue to grow.”

The addition of Mr. Gupta to the board will expand the overall skillset, perspective and experience necessary, to support and drive growth for all of the Company’s stakeholders. 

Mr Gupta’s term will begin during the fourth quarter and he will serve on the audit committee and compensation committees for the duration of his time as a director.

“I am excited about joining the Board of Kraig Labs and look forward to working alongside our Founder and CEO, Kim Thompson and my fellow Board members,” said Mr. Gupta.  “It is exciting to be a part of an innovative biotechnology company that is doing amazing work towards the development and commercialization of Spider Silk technology.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – Sept 13, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that its CEO, Kim Thompson, was recently recognized as one of MyTechMag magazine’s top 20 pioneering CEO’s of 2019.  In the recent CEO edition, Mr Thompson shares the incredible story of the founding of Kraig Labs, as well as how his outsider status and determination delivered success against overwhelming odds. 

In selecting the top 20 pioneering CEO’s of 2019, MyTechMag selection criteria included a review of the complexity of the challenges overcome, the growth of the underlying business, and the CEO’s ability to harness their team’s potential.

“I am honored to have been selected for this recognition.  MyTechMag’s award comes on the verge of a very exciting time for Kraig Labs, as we expect to soon be formally launching commercial scale production of our eco-friendly recombinant spider silk,” said CEO and Founder, Thompson.  “Kraig Labs has been pioneering the way forward for cost effective spider silk production and today’s recognition of my work and our Company’s role in bringing this innovation to market is an honor.  Together, our team has faced and conquered numerous obstacles that stood between us and our goal.  In that spirit I accept this award as recognition for the entire Kraig Labs team, including our valued employees and shareholders.”

You can find a copy of the article at Kraiglabs.com or read the full magazine article at MyTechMag.com or read Mr Thompson’s profile

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – Sept 12, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has narrowed its list of candidates to seven highly qualified individuals to fill the four additional Board of Directors member positions that the Company plans to appoint as part of its preparations for a potential uplist to a national exchange. The Company has received nearly 200 qualified applications for the new board positions. Senior management, after completing vigorous selection process, has narrowed the field down to seven finalists.  These candidates offer a broad and diverse background, ranging from finance and compliance to global operations, marketing, and tech development.  This diversity in experience was intentionally curated, by management, to seat a board able to bring wide ranging knowledge and oversight.

The Company is entering its final selection round and anticipates making a determination, and announcing the appointments, of the new board members, within the next three weeks.

“I am very excited about each of our finalists; I know that those who are ultimately selected will strengthen our Company.  I would like to thank all of the applicants who took the time to go through the selection process,” said Board Chairman and CEO Kim Thompson.

As discussed and approved, by the Company’s shareholders, during the annual shareholder meeting held in July, the appointment of these new board members is part of the Company efforts to position the company for a potential uplist and to strengthen corporate management and oversight as we prepare for production ramp up.

The Company will issue an announcement of the new board members when the selection process in finalized.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

The following is correspondence between the CEO and two of our shareholders which we believe is informative on the Company’s perspective on ballot initiatives for the upcoming shareholder meeting.

Gary,

Thank you for your input and support.

I just responded to another shareholder’s inquiry and am including my response to him below, as some of his concerns overlap yours and I think are representative of questions and input I have received from a few others.

On the question of the preferred stock, I think your concerns have some merit.  Super majorities do have a mixed history.  My intention when I received the preferred back in 2013 was to make sure that we always had the votes necessary to execute on our business plan.  The thinking at that time was that if there was an opportunity for a significant acquisition, merger or up-list, time would be of the essence.  The corporate charter was amended at that time to allow a majority to take such action without a shareholder meeting.  The reason was that it takes significant planing, delays and expense to hold a shareholder meeting and a significant opportunity could slip through our hands in that time.

It is a bit ironic then that, now, when we have a possible opportunity for an up-list, we are never the less holding a meeting of shareholders.  

My small team is fully taxed preparing for the meeting while keeping everything else afloat and executing on our plans for Vietnam.  It is fair to say that I am over-taxed as well.  I will keep an open mind about the super majority and seek input from the team and our securities counsel in the coming weeks and months.

Kim

Kim Thompson, CEO

Kraig Biocraft Laboratories, Inc.

---

Zach,

Thank you for your email.  I am responding to you directly because it looks like you have done your homework on the history of RS.

I do not doubt the Stern data.  Typically when a company does a RS it is because the stock price has been eroding over time and the company can not maintain its exchange listing at the new stock price.  While I have not seen any data, it may also be the case that companies enter into a RS because of covenants on their debt interments or under presser from debt holders. Of course such companies have a tendency to under perform.  They have a history of under-performance.

For Kraig Labs, that is simply not the case.  Our stock has shown significant historical gains (even accounting for the recent pull back) and we are hitting the major milestones we have set for ourselves in terms of setting up production and early stage commercialization.  It is that growth which has given us a possible path to a national exchange.

Historically, we have run this Company on very thin financing.  Now that we need to ramp up production, thin financing will not allow us to ramp up quickly enough to meet our targets or to satisfy the potential customers that we are talking with.

I can not predict the stock price.  I do not know where it is going any more than anyone else.  But I do have strong opinions about what it will take to make the Company a success and what it will take to bring our products to market in a manner that will allow us to beat the competition and capture market share.  My philosophy has always been to focus on the Company’s fundamentals and executing on our business plan.  I do believe that focusing on growing the Company will ultimately benefit our shareholders.

My suggestion would be, that the Stern School data is not as relevant as another set of data.  What happens, statistically, to share price and long term shareholder value when an OTC Company up-lists? 

Our immediate plan to to shoot for the up-list.  There is no guarantee that we will make the up-list.  As I see it we have a relatively small window in which to do this and several moving pieces which need to all move through the window at the same time.  To be frank, my stress levels in engineering and managing this process are very high.  Surprisingly, this is because I think we might just achieve this success and hit the remaining marks in our business plan over the near and medium term.  Some times success itself can be a stresser.  I think the market feels it too.

I know the recent drop in share price is also stressing you and others.  I am personalty affected as well.  But I see opportunity and the possibility of growing this small boat into a bigger and stronger ship.  I chose growth. While I am stressed, I am also excited and, I must confess, elated.

Thank you for your support and your input.  If you chose not to take this ride and see these opportunities through with us I understand.  There are risks, which I do not want to minimize.  It is no my role, as I see it, to convince people to buy the stock or to maintain their investment.  My role it to grow the Company and put in place a strategic vision for market dominance. 

One of the most frustrating aspects of my work is the added burden of being a penny stock and OTC company.  In essence, companies that have made the jump to a national exchange have received at some level a review and participation by investment banks and their client institutions.  Companies which have not gone through that process are always suspect from the perspective of Wall Street and other constituents.  That translates directly to higher costs and closed doors.  If the Company is going to show exponential growth, which is an essential part of our business plan, we need to kick open those doors.  

We are arming ourselves with a battering ram.  I intend to knock on those doors till the hinges come off and the path for our growth is wide open.

Good luck and good fortune to you and for all of us.  

Kim

Kim Thompson, CEO

Kraig Biocraft Laboratories, Inc.